Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Lenalidomide is the approved treatment for patients with red blood cell (RBC) transfusion-dependent lower-risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)). We report the long-term outcomes (median follow-up 3.2 years) in patients treated with lenalidomide in the MDS-003 tria...

Descripción completa

Detalles Bibliográficos
Autores principales: List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017258/
https://www.ncbi.nlm.nih.gov/pubmed/24150217
http://dx.doi.org/10.1038/leu.2013.305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017258/
https://www.ncbi.nlm.nih.gov/pubmed/24150217
http://dx.doi.org/10.1038/leu.2013.305

Ejemplares similares